Sebaceous Carcinoma Incidence and Survival Among Solid Organ Transplant Recipients in the United States, 1987-2017.
暂无分享,去创建一个
M. Tucker | A. Goldstein | C. Lynch | E. Engels | M. Sargen | E. Cahoon | E. K. Cahoon
[1] R. Pfeiffer,et al. Risk of Rare Cancers Among Solid Organ Transplant Recipients , 2020, Journal of the National Cancer Institute.
[2] M. Tucker,et al. Ambient Ultraviolet Radiation and Sebaceous Carcinoma Incidence in the United States, 2000-2016. , 2020, JNCI cancer spectrum.
[3] C. Lynch,et al. Survival after a cancer diagnosis among solid organ transplant recipients in the United States , 2019, Cancer.
[4] C. Hudgens,et al. Distinct Biological Types of Ocular Adnexal Sebaceous Carcinoma: HPV-Driven and Virus-Negative Tumors Arise through Nonoverlapping Molecular-Genetic Alterations , 2018, Clinical Cancer Research.
[5] Charles J. Vaske,et al. Cell of origin and mutation pattern define three clinically distinct classes of sebaceous carcinoma , 2018, Nature Communications.
[6] Amit Sharma,et al. Sebaceous carcinoma in solid organ transplant recipients , 2017, International journal of dermatology.
[7] J. Bordeaux,et al. Incidence and survival of sebaceous carcinoma in the United States. , 2016, Journal of the American Academy of Dermatology.
[8] E. Engels,et al. Elevated Cancer-Specific Mortality Among HIV-Infected Patients in the United States. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] M. Kwon,et al. Comparison of HER2 gene amplification and KRAS alteration in eyelid sebaceous carcinomas with that in other eyelid tumors. , 2015, Pathology, research and practice.
[10] J. Fraumeni,et al. Risk of merkel cell carcinoma after solid organ transplantation. , 2015, Journal of the National Cancer Institute.
[11] K. Kuo,et al. Hypermethylation of the CDKN2A gene promoter is a frequent epigenetic change in periocular sebaceous carcinoma and is associated with younger patient age. , 2014, Human pathology.
[12] W. Weimar,et al. The effect of low and ultra-low dosages Thymoglobulin on peripheral T, B and NK cells in kidney transplant recipients. , 2012, Transplant immunology.
[13] A. Israni,et al. Spectrum of cancer risk among US solid organ transplant recipients. , 2011, JAMA.
[14] A. Mariotto,et al. Improved estimates of cancer-specific survival rates from population-based data. , 2010, Journal of the National Cancer Institute.
[15] D. Schadendorf,et al. Predictors of Sun Protection Behaviors and Severe Sunburn in an International Online Study , 2010, Cancer Epidemiology, Biomarkers & Prevention.
[16] A. Lazar,et al. Adipophilin expression in sebaceous tumors and other cutaneous lesions with clear cell histology: an immunohistochemical study of 117 cases , 2010, Modern Pathology.
[17] J. Fraumeni,et al. Epidemiology of nonkeratinocytic skin cancers among persons with AIDS in the United States , 2009, AIDS.
[18] L. Wilson,et al. A retrospective review of 1349 cases of sebaceous carcinoma , 2009, Cancer.
[19] J. Goedert,et al. Cancer risk in people infected with human immunodeficiency virus in the United States , 2008, International journal of cancer.
[20] J. Fishman. Infection in solid-organ transplant recipients. , 2007, The New England journal of medicine.
[21] David B Buller,et al. Reducing ultraviolet radiation exposure among outdoor workers: State of the evidence and recommendations , 2007, Environmental health : a global access science source.
[22] W. Lee,et al. Improved survival rates in sebaceous carcinoma of the eyelid , 2004, Eye.
[23] M. Furihata,et al. Search for accumulation of p53 protein and detection of human papillomavirus genomes in sebaceous gland carcinoma of the eyelid , 2004, Virchows Archiv.
[24] J. McGregor,et al. High frequency and diversity of cutaneous appendageal tumors in organ transplant recipients. , 2003, Journal of the American Academy of Dermatology.
[25] V. Bataille,et al. An association between sebaceous carcinoma and microsatellite instability in immunosuppressed organ transplant recipients. , 2001, The Journal of investigative dermatology.
[26] P. Levine,et al. Sebaceous carcinoma: Tumor progression through mutational inactivation of p53 , 1998 .